skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

This content will become publicly available on June 19, 2020

Title: An Overview of Genomic Biomarker Use in Cardiovascular Disease Clinical Trials

Authors:
 [1];  [1];  [1];  [1];  [2];  [1];  [1]
  1. Office of Clinical PharmacologyOffice of Translational SciencesCenter for Drug Evaluation and ResearchUS Food and Drug Administration Silver Spring Maryland USA
  2. ORISE FellowOffice of Clinical PharmacologyOffice of Translational SciencesCenter for Drug Evaluation and ResearchUS Food and Drug Administration Silver Spring Maryland USA, Department of BioengineeringStanford University Palo Alto California USA
Publication Date:
Sponsoring Org.:
USDOE
OSTI Identifier:
1559368
Resource Type:
Publisher's Accepted Manuscript
Journal Name:
Clinical Pharmacology and Therapeutics
Additional Journal Information:
Journal Name: Clinical Pharmacology and Therapeutics Journal Volume: 106 Journal Issue: 4; Journal ID: ISSN 0009-9236
Publisher:
Wiley Blackwell (John Wiley & Sons)
Country of Publication:
United States
Language:
English

Citation Formats

Adeniyi, Oluseyi, Ramamoorthy, Anuradha, Schuck, Robert, Sun, Jielin, Wilson, Jennifer, Zineh, Issam, and Pacanowski, Michael. An Overview of Genomic Biomarker Use in Cardiovascular Disease Clinical Trials. United States: N. p., 2019. Web. doi:10.1002/cpt.1473.
Adeniyi, Oluseyi, Ramamoorthy, Anuradha, Schuck, Robert, Sun, Jielin, Wilson, Jennifer, Zineh, Issam, & Pacanowski, Michael. An Overview of Genomic Biomarker Use in Cardiovascular Disease Clinical Trials. United States. doi:10.1002/cpt.1473.
Adeniyi, Oluseyi, Ramamoorthy, Anuradha, Schuck, Robert, Sun, Jielin, Wilson, Jennifer, Zineh, Issam, and Pacanowski, Michael. Mon . "An Overview of Genomic Biomarker Use in Cardiovascular Disease Clinical Trials". United States. doi:10.1002/cpt.1473.
@article{osti_1559368,
title = {An Overview of Genomic Biomarker Use in Cardiovascular Disease Clinical Trials},
author = {Adeniyi, Oluseyi and Ramamoorthy, Anuradha and Schuck, Robert and Sun, Jielin and Wilson, Jennifer and Zineh, Issam and Pacanowski, Michael},
abstractNote = {},
doi = {10.1002/cpt.1473},
journal = {Clinical Pharmacology and Therapeutics},
number = 4,
volume = 106,
place = {United States},
year = {2019},
month = {4}
}

Journal Article:
Free Publicly Available Full Text
This content will become publicly available on June 19, 2020
Publisher's Version of Record

Save / Share:

Works referenced in this record:

Global Requirements for DNA Sample Collections: Results of a Survey of 204 Ethics Committees in 40 Countries
journal, February 2011

  • Ricci, D. S.; Broderick, E. D.; Tchelet, A.
  • Clinical Pharmacology & Therapeutics, Vol. 89, Issue 4
  • DOI: 10.1038/clpt.2010.319

Occlusion in the Flow of New Drugs for Cardiovascular Disease
journal, June 2017

  • Ringel, Ms; Shah, Na; Baedeker, M.
  • Clinical Pharmacology & Therapeutics, Vol. 102, Issue 2
  • DOI: 10.1002/cpt.691

Cardiovascular Drug Development
journal, April 2015

  • Fordyce, Christopher B.; Roe, Matthew T.; Ahmad, Tariq
  • Journal of the American College of Cardiology, Vol. 65, Issue 15
  • DOI: 10.1016/j.jacc.2015.03.016

Open Targets: a platform for therapeutic target identification and validation
journal, November 2016

  • Koscielny, Gautier; An, Peter; Carvalho-Silva, Denise
  • Nucleic Acids Research, Vol. 45, Issue D1
  • DOI: 10.1093/nar/gkw1055

Genome Sequence Variability Predicts Drug Precautions and Withdrawals from the Market
journal, September 2016


Cardiovascular disease: The rise of the genetic risk score
journal, March 2018


The support of human genetic evidence for approved drug indications
journal, June 2015

  • Nelson, Matthew R.; Tipney, Hannah; Painter, Jeffery L.
  • Nature Genetics, Vol. 47, Issue 8
  • DOI: 10.1038/ng.3314

Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012
journal, August 2016

  • Hwang, Thomas J.; Lauffenburger, Julie C.; Franklin, Jessica M.
  • JACC: Basic to Translational Science, Vol. 1, Issue 5
  • DOI: 10.1016/j.jacbts.2016.03.012

Clinical development success rates for investigational drugs
journal, January 2014

  • Hay, Michael; Thomas, David W.; Craighead, John L.
  • Nature Biotechnology, Vol. 32, Issue 1
  • DOI: 10.1038/nbt.2786

Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012
journal, January 2014


Tracking the Pharmaceutical Pipeline: Clinical Trials and Global Disease Burden: Tracking the Pharmaceutical Pipeline
journal, May 2014

  • Cottingham, Marci D.; Kalbaugh, Corey A.; Fisher, Jill A.
  • Clinical and Translational Science, Vol. 7, Issue 4
  • DOI: 10.1111/cts.12163

Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009
journal, December 2010

  • Kaitin, K. I.; DiMasi, J. A.
  • Clinical Pharmacology & Therapeutics, Vol. 89, Issue 2
  • DOI: 10.1038/clpt.2010.286

Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities
journal, July 2017


Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
journal, August 2018


Genetics and Genomics for the Prevention and Treatment of Cardiovascular Disease: Update: A Scientific Statement From the American Heart Association
journal, December 2013


The State of US Health, 1990-2010: Burden of Diseases, Injuries, and Risk Factors
journal, August 2013


The productivity crisis in pharmaceutical R&D
journal, June 2011

  • Pammolli, Fabio; Magazzini, Laura; Riccaboni, Massimo
  • Nature Reviews Drug Discovery, Vol. 10, Issue 6
  • DOI: 10.1038/nrd3405

Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond
journal, July 2016


Current Practices for DNA Sample Collection and Storage in the Pharmaceutical Industry, and Potential Areas for Harmonization: Perspective of the I-PWG
journal, March 2011

  • Franc, M. A.; Warner, A. W.; Cohen, N.
  • Clinical Pharmacology & Therapeutics, Vol. 89, Issue 4
  • DOI: 10.1038/clpt.2010.338

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
journal, May 2014

  • Cook, David; Brown, Dearg; Alexander, Robert
  • Nature Reviews Drug Discovery, Vol. 13, Issue 6
  • DOI: 10.1038/nrd4309